{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:07:52Z","timestamp":1777421272018,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2016,5,30]],"date-time":"2016-05-30T00:00:00Z","timestamp":1464566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p>Background: There are little evidences about the therapeutic efficacy of different lipid-lowering agents in the reduction of elevated lipoprotein(a) [Lp(a)]. Objective: testing the effect of different lipid-lowering agents on elevated Lp(a). Methods: prospective interventional study performed in patients with CAD, or high CAD risk, with Lp(a), &gt;50 mg\/dL. Lp(a), total cholesterol (C), HDL-C, LDL-C, triglycerides (TGs), apolipoprotein (Apo) A1, Apo B, enzymes of myocyte and hepatic injury were comparatively analyzed between 4 lipid-lowering strategies: rosuvastatin (R group) 40 mg, atorvastatin (A group) 80 mg, atorvastatin 40 mg add-on micronized fenofibrate (A+F group), and atorvastatin 40 mg add-on 1 g extended-release niacin (A+ERN group). Comparison was made for their therapeutic efficacy on Lp(a), and safety. Results: 87 patients with mean Lp(a) 94.6 \u00b1 39.6 mg\/dL were analyzed. Groups: 25 patients in the R, 22 in the A, 20 in the A+F and 20 in A+ERN group. Significant reduction in all lipid fractions in all treatment groups was reported after 6 months. The average reduction of Lp(a) was 15.9 \u00b1 21.0 mg\/dL, with: 18.2 \u00b1 24.8 ( P = 0.001) in the R group, 17.3 \u00b1 10.4 (P = 0.001) in A+F, 19.5 \u00b1 10.9 (P = 0.001) in A+ERN and the lowest in the A group (11.24 \u00b1 22.91, P = 0.032). No adverse effects were observed in any of the treatment groups. Conclusions: When compared with atorvastatin, it seems that rosuvastatin can achieve more significant decrease of Lp(a).The efficacy of the second one can be increased by adding fibrate or ERN.<\/jats:p>","DOI":"10.1177\/1060028016652415","type":"journal-article","created":{"date-parts":[[2016,5,30]],"date-time":"2016-05-30T21:53:59Z","timestamp":1464645239000},"page":"609-615","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a)"],"prefix":"10.1177","volume":"50","author":[{"given":"Marija","family":"Vavlukis","sequence":"first","affiliation":[{"name":"Ss Cyril and Methodius University, Skopje, Republic of Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Mladenovska","sequence":"additional","affiliation":[{"name":"Ss Cyril and Methodius University, Skopje, Republic of Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlinda","family":"Daka","sequence":"additional","affiliation":[{"name":"Hasan Prishtina University, Prishtina, Republic of Kosovo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandar","family":"Dimovski","sequence":"additional","affiliation":[{"name":"Ss Cyril and Methodius University, Skopje, Republic of Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saska","family":"Domazetovska","sequence":"additional","affiliation":[{"name":"Ss Cyril and Methodius University, Skopje, Republic of Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Kuzmanovska","sequence":"additional","affiliation":[{"name":"Ss Cyril and Methodius University, Skopje, Republic of Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasko","family":"Kedev","sequence":"additional","affiliation":[{"name":"Ss Cyril and Methodius University, Skopje, Republic of Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,5,30]]},"reference":[{"key":"bibr1-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.12.023."},{"key":"bibr2-1060028016652415","first-page":"54","volume":"77","author":"Duriez P","year":"1996","journal-title":"Br J Clin Pract Suppl"},{"key":"bibr3-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.715698."},{"key":"bibr4-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr158."},{"key":"bibr5-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq386."},{"key":"bibr6-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a."},{"key":"bibr7-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1517\/13543781003623223."},{"key":"bibr8-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.09.060."},{"key":"bibr9-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004406."},{"key":"bibr10-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-013-0358-6."},{"key":"bibr11-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61252-1"},{"key":"bibr12-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2012.10.035."},{"key":"bibr13-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000126."},{"key":"bibr14-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000126."},{"key":"bibr15-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2010.01.029."},{"key":"bibr16-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.11.037."},{"key":"bibr17-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300955."},{"key":"bibr18-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001282."},{"key":"bibr19-1060028016652415","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(02)00072-2."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028016652415","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028016652415","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028016652415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:23Z","timestamp":1777374983000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028016652415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,30]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1177\/1060028016652415"],"URL":"https:\/\/doi.org\/10.1177\/1060028016652415","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,30]]}}}